



UPPSALA
UNIVERSITET

Uncertainty quantification methods for complex models used in drug development and/or regulatory approval

[Andrew C. Hooker](#)

Professor of Pharmacometrics

Dept. of Pharmacy, Uppsala University

Uppsala, Sweden

CONFIRMS Consortium

2025-10-08



CONsortium For Innovation in Regulatory Medical Statistics - CONFIRMS

- [Pharmacometrics Research Group](#) at **Uppsala University (UU)**
 - Andrew Hooker, Mats Karlson, Xiaomei Chen, Yevgen Ryeznic, Zhe Huang
 - Sub-contractor: **Swedish Medical Products Agency (MPA)**, Robin Svensson
- [Center for Medical Data Science](#) (CEDAS), **Medical University of Vienna (MUW)**
 - Martin Posch, Franz König
- [Department of Medical Statistics](#), **University Medical Center Göttingen (UMG)**
 - Tim Friede, Norbert Benda, Paula Starke, Lucia Schneider
- **Austrian Medicines and Medical Devices Agency (MEA)**, a business division of the Austrian Agency for Health and Food Safety (**AGES**)
 - Florian Klinglmueller, Tobias Fellingner, Elham Yousefi, Lynette Caitlin Mikula

Uncertainty in Complex Models: Key Challenges

- **Role of Complex Models:** Physiologically Based Pharmacokinetic (PBPK), quantitative systems pharmacology (QSP), and machine learning (ML) models are essential for drug development tasks like dose prediction, drug-drug interaction assessment, and clinical trial design.
- **Current Limitations:**
 - Parameters often fixed without accounting for uncertainty or variability.
 - Discrepancies assessed using simplistic metrics (e.g., fold prediction error), which lack sensitivity and pharmacological relevance.
- **Gap & Opportunity:**
 - No widely accepted uncertainty quantification (UQ) methods for complex models.
 - Emerging UQ techniques can improve model credibility and support regulatory decision-making.

Confirms consortia project objectives

1. **Identify UQ Methods (literature review):** Summarize current statistical methods applicable to complex models (PBPK, QSP, ML) for drug development and regulatory use.
2. **Assess Performance:** Conduct simulations to evaluate selected methods under various settings and derive recommendations.
3. **Promote Application:** Publish results and provide an easy-to-use toolkit with tutorials for implementing UQ in complex modeling.

Literature Review


Two parts:

1. **Literature Review:** The review identifies UQ methods in PBPK, QSP, ML models and cross-disciplinary techniques from other sciences
2. **Review of regulatory procedures where uncertainty quantification of mechanistic models was of concern:** The review identifies EMA procedures discussing UQ, maps methods, and summarizes regulatory recommendations.

Literature review (part 1)

Literature Review Workflow (Adaptive Approach)

- **Adaptive Workflow**: An adaptive approach was taken to refine searches to balance completeness and feasibility.
- **Databases**: PubMed, MathSciNet, Scopus.
- **Search Terms**:
 - Core: uncertainty
 - Methods: Bayesian calibration, surrogate modeling, sensitivity analysis, etc.
 - Models: PBPK, QSP, ML.
- **Tools Used**:
 - Rayyan – abstract screening
 - Zotero – full-text retrieval
 - Elicit – data extraction
- **Outcome**: Organized dataset of UQ methods across PBPK/QSP/ML models.



Search Strategy Details

- **Databases & Keywords:**

- PubMed, MathSciNet, Scopus
- Combine UQ terms with PBPK/QSP/ML using “AND.”


- **Screening Process:**


- Import results into Rayyan
- Apply inclusion/exclusion criteria
- Two reviewers screen independently; third resolves conflicts

- **Extraction Process:**


- Retrieve full texts via Zotero
- Use Elicit (AI tool) for initial extraction, followed by manual verification
- Summarize results in Excel

PRISMA 2020 flow diagram






Type of complex model in included articles



UQ methods in all included articles




EPARS/SA review (part 2)


Search Strategy and Eligibility Criteria

- **Data Sources Utilized:** The review sourced information from EMA Public Assessment Reports and EMA Scientific Advice Final Letters databases.
- **Structured Search Method:** A structured search using predefined keywords focused on mechanistic modeling and uncertainty quantification was conducted.
- **Eligibility Criteria Defined:** Included procedures discussed mechanistic models and UQ methods before June 1, 2025; exclusions applied for lack of regulatory UQ discussion.
- **Data Screening and Analysis:** Screening and data extraction used standardized forms, followed by descriptive statistical analysis.


PRISMA 2020 flow diagram



Number of models by modelling context



Number of models by type



Regulatory discussion

- Only brief discussion of UQ – 65%
- Reviewers were asked to assess whether the regulatory discussion indicated that UQ of the modelling approach—or the uncertainty reflected in the model results supported by various UQ methods—was considered adequate
 - Adequate - 50/108 (46%)
 - Unclear – 32/108 (30%)
 - Inadequate – 26/108 (24%)


Summary and Implications for Drug Development

- **Gap in UQ Methods:** There is a significant gap in well-established uncertainty quantification methods for complex drug development models.
- **Current UQ Practices in regulatory assessment:**
 - Uncertainty quantification in EMA regulatory procedures are often discussed at a high level without detail in the methods.
 - Findings highlight the necessity for standardized and comprehensive UQ methodologies in regulatory settings.
- **Promising UQ Techniques:** Techniques like global sensitivity analysis, uncertainty propagation, and Bayesian methods enhance model reliability and applicability.
- **Importance for Model Robustness:** Appropriate UQ methods improve the robustness of PBPK, QSP, and machine learning models in drug development.
- **Future Simulation Studies:** Future studies will refine UQ practices and support regulatory decision-making with robust evidence.

Acknowledgements and further reading

- EMA funding: FWC/EMA/2020/46/L3-ROC22-SC02
- Full report on this literature/EPAR/SA review can be found at:
<https://catalogues.ema.europa.eu/node/4620/administrative-details>

Literature review workflow



Database Searching Methodology: Structured searches used PubMed, MathSciNet, and Scopus with refined keywords and fuzzy search techniques for best coverage and relevance.

Screening and Selection Process: Abstracts were screened using Rayyan software with clear inclusion and exclusion criteria for relevant paper selection.

Full-Text Extraction and Data Organization: Full texts were retrieved via Zotero and data extracted using AI tools (Elicit), then organized into detailed spreadsheets for accuracy.

Manual Verification Ensures Accuracy: Manual checks were performed to verify data accuracy and properly categorize papers and uncertainty quantification methods.

Step 1: Search in databases

- **Databases**
 - PubMed (for medical field)
 - MathSciNet (mathematics & statistics)
 - Scopus (wide ranges of topic)
- **Structured search terms:**
 - 1. Uncertainty quantification/analysis**
 - **core term:** uncertainty
 - **specific methods:** Bayesian hierarchical meta-regression, Bayesian calibration, model discrepancy analysis, surrogate modeling, probabilistic sensitivity analysis, uncertainty propagation, interval analysis, fuzzy computations, frequentist.
 - 2. Complex models**
 - **PBPK & QSP related models:** Physiologically based pharmacokinetic modeling (PBPK), Physiologically based biopharmaceutics modeling (PBBM), Quantitative systems pharmacology (QSP), PBPK model used in toxicology (study toxin instead of drugs), Quantitative Systems Toxicology (QST)
 - **Machine learning (ML) models**
 - 3. Use “AND” for the above two fields**

Quality control:

Check that the resultant search includes the following papers and results in a feasible number of papers to review, if not, redefine search terms.

1. Kennedy MC, O'Hagan A. Bayesian calibration of computer models. *Journal of the Royal Statistical Society Series B: Statistical Methodology*. 2001;63:425–64
2. Lash TL, Fox MP, MacLehose RF, Maldonado G, McCandless LC, Greenland S. Good practices for quantitative bias analysis. *International Journal of Epidemiology*. 2014;43:1969–85
3. Strong M, Oakley JE. When is a model good enough? Deriving the expected value of model improvement via specifying internal model discrepancies. *SIAM/ASA Journal on Uncertainty Quantification*. 2014;2:106–25
4. Owen, N. E., Challenor, P., Menon, P. P., & Bennani, S. (2017). Comparison of surrogate-based uncertainty quantification methods for computationally expensive simulators. *SIAM/ASA Journal on Uncertainty Quantification*, 5(1), 403-435.

Step 2: Screening abstracts & Criteria

- Import search results into **Rayyan** for screening.
- Apply inclusion/exclusion criteria.
- Two reviewers screen independently; third resolves conflicts.
- **Inclusion:** UQ methods, case studies (PBPK, QSP, ML), other relevant models.
- **Exclusion:** Not relevant to UQ, UQ only for estimation (e.g., local sensitivity), or full text unavailable.

Step 3: Extract information from full texts: **general procedures**

- Retrieve Full Texts

Access papers via **Zotero** → Exclude those without full text access at Uppsala University or University Medical Center Göttingen and remove duplicates.

- Information Extraction

Use **Elicit** for initial data extraction, define and train the instructions for the columns on 10 papers and apply on all papers.

- Manual Verification


Check extracted information from all papers manually. If **Elicit** is wrong, the information will be corrected manually.

- Summarize results via **Excel**.

Step 3: Extract information from full texts: **Information to extract**


Search results are organized in a table with following 20 columns:

- ID
- Title
- Authors
- Source/Journal
- Year
- DOI/Full Text link
- Inclusion? (yes/no)
 - If no inclusion, reason
- Type of paper
(Methodology/Application/Review)
- Type of model (PBPK/QSP/ML/Others)**
- UQ methods**
- If it is related to drug development**
 - Purpose of the model
 - Type of the product : small molecule, biologics
 - Therapeutic area
 - Stage of drug development
- Simulation? (yes/no)**
- Software availability?
(Open source/Commercial/Open source+Commercial/No)
- Software used
- Code availability? (Open source/Commercial platform with given parameters/upon the request to the authors/No)
- Comments



Absolute number of
articles by type of
models in the “Others”
category (n=159)

Related to drug development




Categorisation Uncertainty Quantification methods

- Screening process without predefined classification of all UQ methods
- Extraction of specific method names and general keywords like sensitivity analysis and uncertainty propagation

List of methods and keywords

- Morris method
- Monte Carlo simulation
- Polynomial Chaos Expansion
- Fuzzy computation
- Monte Carlo dropout
- Bayesian hierarchical modeling
- Uncertain differential equations
- ...

Categorisation

- 
- Global sensitivity analysis
 - Uncertainty propagation
 - Bayesian methods
 - UDE/SDE
 - ...

Categorisation Uncertainty Quantification methods


- Screening process without predefined classification of all UQ methods
- Extraction of specific method names and general keywords like sensitivity analysis and uncertainty propagation

List of methods and keywords


- Morris method
- Monte Carlo simulation
- Polynomial Chaos Expansion
- Monte Carlo dropout
- Bayesian hierarchical modeling
- ...

Categorisation


- Global sensitivity analysis
 - Simulation-based
 - Analytical
 - ...
- Bayesian methods
 - Bayesian ML
 - Hierarchical modeling
 - ...



UQ methods for PBPK/QSP models since 2015



Software specified for articles with simulation?



Code available for articles with simulation?

